General MedicationsTOPICALGeneric

DESONATE

DESONIDE

Standard Dose

0.05% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

Max Dose

Refer to approved labeling

Primary Use

Review priority: STANDARD Marketing status: Discontinued

Summary

Approval overview DESONATE is listed in Drugs@FDA under application 021844 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient DESONIDE Form and strength GEL;TOPICAL - 0.05% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor LEO PHARMA AS Submission history Latest submission status date: 2016-03-14 00:00:00.

Structured Monograph

Clinical summary

Approval overview DESONATE is listed in Drugs@FDA under application 021844 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient DESONIDE Form and strength GEL;TOPICAL - 0.05% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor LEO PHARMA AS Submission history Latest submission status date: 2016-03-14 00:00:00. Submission type: SUPPL.

Monitoring

• Marketing status: Discontinued
• Review priority: STANDARD

Interaction Notes

No interaction notes stored yet.